GAM
CORT icon

Gemmer Asset Management’s Corcept Therapeutics CORT Stock Holding History

Gemmer Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-197
Closed -$2K – 1380
2019
Q1 		$2K Buy
197
+10
+5% +$124 ﹤0.01% 1258
2018
Q4 		$2K Buy
+187
New +$2.47K ﹤0.01% 1198

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Gemmer Asset Management's CORT Position: Q2 2019 in Review

Gemmer Asset Management sold out of Corcept Therapeutics (CORT) in Q2 2019, closing a stake of 197 shares — an estimated $2K sold.

Gemmer Asset Management first reported a position in CORT in Q4 2018 and held it in 2 quarters. The position peaked at $2K in Q1 2019. 183 funds tracked by Wall St. Rank hold CORT as of Q2 2019.

  • Gemmer Asset Management reported no remaining Corcept Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Gemmer Asset Management sold 197 Corcept Therapeutics shares in Q2 2019, an estimated $2K.
  • Gemmer Asset Management first reported a position in Corcept Therapeutics in Q4 2018 and held it in 2 quarters.
  • Gemmer Asset Management's Corcept Therapeutics position peaked at $2K in Q1 2019.
  • 183 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2019.

Based on Gemmer Asset Management's 13F filing for Q2 2019, filed 18 Jul 2019.